RAYMOND BUNCH, MD
Psychiatric at Thomas Rd, Phoenix, AZ
License number
Arizona 36162
Category
Psychiatric
Type
Child & Adolescent Psychiatry
Address
Address
1919 E Thomas Rd DEPARTMENT PSYCHIATRY, Phoenix, AZ 85016
Phone
(602) 933-0990
(602) 933-0401 (Fax)
(602) 512-8029
(602) 512-8161 (Fax)
(602) 933-0401 (Fax)
(602) 512-8029
(602) 512-8161 (Fax)
Personal information
See more information about RAYMOND BUNCH at radaris.comName
Address
Phone
4872 Rose Ln, Glendale, AZ 85301
6202 Oregon Ave, Glendale, AZ 85301
6725 Utopia Rd, Glendale, AZ 85308
1919 Thomas, Phoenix, AZ 85016
6725 W Utopia Rd, Glendale, AZ 85308
Organization information
See more information about RAYMOND BUNCH at bizstanding.comRaymond Bunch MD
1919 E Thomas Rd, Phoenix, AZ 85016
Industry:
Psychiatrist
Site:
Phone:
(602) 933-0990 (Phone)
Raymond William Bunch
Professional information
See more information about RAYMOND BUNCH at trustoria.com
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2009006, Mar 12, 2009
Filed:
Jul 25, 2008
Appl. No.:
12/180373
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
International Classification:
A61K 31/7076, A61K 31/551, A61K 31/519, A61K 31/137, A61K 31/55, A61P 25/28
US Classification:
514 46, 514220, 51425941, 514651, 514217, 51421113
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2012007, Mar 22, 2012
Filed:
Mar 18, 2011
Appl. No.:
13/051950
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen Elizabeth Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen Elizabeth Stevens - Westminster CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 31/7076, A61K 31/53, A61K 31/196, A61K 31/55, A61K 31/19, A61K 31/551, A61K 31/4178, A61K 31/15, A61K 31/138, A61K 31/135, A61P 25/08, A61P 25/00, A61P 25/18, A61P 25/28, A61P 25/24, A61P 25/20, A61P 25/22, A61K 31/27
US Classification:
514 46, 514483, 514242, 514562, 514217, 514557, 514220, 514397, 514664, 514651, 514647, 514656
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Raymond William Bunch, Phoenix AZ
Raymond William Bunch, Phoenix AZ
Specialties:
Child and Adolescent Psychiatrist
Address:
1919 E Thomas Rd, Phoenix, AZ 85016
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology)*, American Board of Psychiatry and Neurology Sub-certificate in Child and Adolescent Psychiatry (Psychiatry and Neurology)*
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2009020, Aug 20, 2009
Filed:
Jan 17, 2007
Appl. No.:
12/161149
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 31/7076, A61K 31/27, A61K 31/53, A61K 31/195, A61K 31/19, A61K 31/55, A61K 31/551, A61K 31/4178, A61K 31/135, A61P 25/18
US Classification:
514 46, 514483, 514242, 514562, 514557, 514217, 514220, 514397, 514646
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Dr. Raymond Bunch, Phoenix AZ - MD (Doctor of Medicine)
Dr. Raymond Bunch, Phoenix AZ - MD (Doctor of Medicine)
Specialties:
Child & Adolescent Psychiatry
Address:
Phoenix Children's Hospital PSY
1919 E Thomas Rd, Phoenix 85016
(602) 546-0990 (Phone)
1919 E Thomas Rd, Phoenix 85016
(602) 546-0990 (Phone)
Certifications:
Child & Adolescent Psychiatry, 2009, Psychiatry, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of Colorado School Of Medicine
Graduated: 2000
University Of Colorado School Of Medicine
Graduated: 2000
Multi-Parameter Monitoring Device For Use With Central And Intravenous Administration Of Medication
Multi-Parameter Monitoring Device For Use With Central And Intravenous Administration Of Medication
US Patent:
2009022, Sep 3, 2009
Filed:
Jan 22, 2007
Appl. No.:
12/161302
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Michael Royals - Pierce CO, US
Raymond Bunch - Phoenix AZ, US
Michael Royals - Pierce CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61M 5/142
US Classification:
604 66
Abstract:
The invention generally relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being centrally administered in connection with treatment of a CNS-related condition or disorder, e.g., a neuro-psychiatric disorder. In another aspect, the invention relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being (a) intravenously administered to a patient in connection with a treatment, such as is the case where the therapeutic agent solution comprises an IV administerable solution, or (b) administered to a patient in connection with a treatment for diabetes, such as is the case where the therapeutic agent comprises insulin.